IT Roars Back — Nifty +0.89% to 24,271, Sensex +0.86% to 77,764; a Soft US Jobs Print Cements a Fed-on-Hold, VIX Sinks to a February Low, and the Market Books a Fourth Straight Weekly Gain with Pharma at a Record High
Cautiously OptimisticAfter a quiet fortnight, the market found a fresh gear — and it came from the sector everyone had written off. Indian equities climbed steadily through the five sessions to a fourth consecutive weekly gain, the longest winning run of 2026 so far. The benchmarks closed firmly higher — the Nifty 50 added 0.89% to 24,270.85 (about +215 points) and the Sensex rose 0.86% to 77,763.91 (about +663 points), both up nearly a full percent on the week. The engine was a striking rebound in IT: after being routed just three weeks earlier on Accenture's FY27 guidance cut, the Nifty IT index bounced roughly 4% off a four-day fall, with Infosys and TCS surging up to 5%. Pharma led alongside — the Nifty Pharma index hit a fresh record high of 25,861.50 as Aurobindo, Ipca, Laurus and Torrent touched all-time highs. Crucially, the advance was broad-based: BSE Midcaps (+0.80%) and Smallcaps (+1.51%) rose too, and the fear gauge fell further, India VIX dropping about 10% to 11.79 — its lowest since February. The week's single clear driver came from Washington: a soft US June jobs report (just 57,000 jobs added versus ~113,000 expected, unemployment 4.2%, with prior months revised lower) cemented the case for the Fed to stay on hold, switching global risk appetite firmly back on and powering US indices to fresh highs (S&P 500 +1.8%, Nasdaq +2.1%, Dow +2%). That softer-rates signal flowed straight into India's IT rebound, drew foreign buyers back (FIIs turned net buyers ~+₹4,200 Cr while DIIs added ~+₹12,600 Cr, both provisional), and kept crude soft (Brent ~$72/bbl) and the rupee steady (~₹94.9). The week's real lesson is behavioural: selling into a sector scare — as many were tempted to do with IT three weeks ago — costs an investor twice, the fall and then the rebound they miss. (Figures are as of the Friday 3 July close; items that could not be independently cross-verified are stated approximately or omitted.)
Key Points This Week
- 1Nifty 50 closed at 24,270.85 (Fri 3 Jul), up about 0.89% week-on-week from 24,056.00; the Sensex settled at 77,763.91, up roughly 0.86% from 77,100.47. Both benchmarks rose nearly a full percent, notching a fourth consecutive weekly gain — the longest winning run of 2026 so far. The two moved together throughout, as they always do, and the advance built steadily across the five sessions rather than in one sharp move.
- 2THE ENGINE WAS AN IT REBOUND. After being routed just three weeks earlier on Accenture's FY27 guidance cut, the Nifty IT index bounced roughly 4% off a four-day fall, with Infosys and TCS surging up to 5%. The trigger was global: softer US rate expectations revived appetite for the rate-sensitive, export-facing sector, aided by short-covering. It is a textbook illustration that the corner of the market you fear most this month can lead the very next — which is exactly why reacting to a single sector scare is so costly.
- 3PHARMA HIT A RECORD HIGH. The Nifty Pharma index touched a fresh all-time high of 25,861.50 (up about 2% on Friday), with Aurobindo Pharma, Ipca Laboratories, Laurus Labs and Torrent Pharmaceuticals among the names at record levels. Healthcare has quietly been one of 2026's standout pockets — a reminder that leadership is broad and rotating, and that a diversified core captures these winners without needing to pick them in advance.
- 4THE ADVANCE WAS BROAD-BASED. Unlike the prior fortnight's narrow, defensive drift, this week saw the whole market rise together — BSE Midcaps added about 0.80% and Smallcaps about 1.51%, outpacing the large-cap benchmarks (provisional aggregator data). A rising market with broad breadth AND falling volatility — India VIX slipped roughly 10% to 11.79, its lowest since February — is about as constructive a technical combination as it gets, though never a reason to chase.
- 5THE DRIVER CAME FROM WASHINGTON. US June payrolls came in soft — just 57,000 jobs added versus about 113,000 expected, unemployment at 4.2%, with prior months revised lower — breaking a hot streak and cementing the case for the Fed to stay on hold. That "bad news is good news" read switched global risk appetite firmly back on, lifting US indices to fresh highs in a holiday-shortened week (S&P 500 +1.8%, Nasdaq +2.1%, Dow +2%; US markets shut Friday for Independence Day). Even Bitcoin rose about 4% on the week, to near $61,500, on the same easing-rates narrative.
- 6FLOWS TURNED FRIENDLIER. The notable shift was foreign money coming back: FIIs turned net buyers on the cash tape (roughly +₹4,200 Cr, provisional) — a welcome reversal after months of selling — as the IT rebound drew them in, while domestic institutions stayed strong buyers (about +₹12,600 Cr). Crude stayed soft near $72/bbl on easing West Asia tensions, and the rupee held steady around ₹94.9, both quiet tailwinds for an economy that imports over 80% of its oil. Whether the foreign buying persists into earnings season is the key flow to watch.
SIP Investor Advice
This week is a live, uncomfortable lesson in the true cost of reacting to a scare — and the most useful conversation a client can have this fortnight is about IT. (1) Understand that selling a scare costs you twice. Three weeks ago, one guidance cut from Accenture triggered an IT sell-off and a wave of "is the sector broken?" headlines. An investor who acted on that fear — who trimmed IT, or worse, paused their SIP — locked in the fall and then watched from the sidelines this week as the very same sector bounced ~4% and led the market to a fresh high. You do not just take the loss; you also forfeit the recovery, which almost never announces itself in advance. As Peter Lynch put it, "The real key to making money in stocks is not to get scared out of them." (2) Let broad gains reward diversification, not sector-picking. This week large, mid and small-caps ALL rose, and the leaders were IT, pharma and realty — the very corners that had lagged in June. Owning the whole market through a diversified, multi-cap core is what captured that rotation automatically; trying to guess which sector leads next is a gamble you do not need to take. (3) Treat the coming earnings season as information, not instruction. Q1 FY27 results start shortly, with IT majors traditionally reporting first. Read them for context on how your funds' holdings are doing — do not trade the headlines. A single quarter's guidance moved IT violently in both directions within three weeks; your 10-year goal should not be steered by either move. (4) Do not confuse a calm, rising market for a signal to chase. Volatility at a February low and a fourth straight up week feel good, but the discipline is identical to a scary week — keep the SIP running, keep the allocation aligned to your goal, and resist both fear and greed. (5) The single most useful step this fortnight is a calm allocation-and-quality review with your Trustner Relationship Manager: confirm you are on track to your goals and that your funds are in good hands, precisely so the next scary headline — and there will always be one — is something you can sit through rather than react to. This week's companion blog, "The Rebound You'd Have Missed: Why Selling a Sector Scare Costs You Twice," unpacks the full idea. Stay invested, keep your SIPs running, keep your eyes on the goal — not the ticker.
Market data shown is illustrative/sample only. Not real-time. All information is for educational purposes and should not be construed as investment advice. Past performance does not guarantee future returns.